Cargando…
Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios
Cemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was given every 2 weeks for up to 96 weeks, a 44% response rate was noted. This case serie...
Autores principales: | Akhtar, Komal, Sravanthi, Metlapalli Venkata, D’Angelo, Josephine, Sivapiragasam, Abirami |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421057/ https://www.ncbi.nlm.nih.gov/pubmed/36017984 http://dx.doi.org/10.1177/23247096221121408 |
Ejemplares similares
-
Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022) -
Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022) -
Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Lai, Fei Ya, et al.
Publicado: (2023) -
Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
por: Van Meerhaeghe, T., et al.
Publicado: (2022) -
Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma
por: Virgen, Cesar A., et al.
Publicado: (2020)